Alcon's Minority Shareholders Face Double-Whammy

Novartis is finally closing the deal on its pursuit of eye-care firm Alcon. But there's a twist: The price per share it's paying for Nestle's majority stake is far better than it's giving minority shareholders. And to add insult to injury, they face negative tax implications, too.